ClearPoint Neuro Q3 revenue $4.6M record, up 30% YoY; reaffirms FY guidance

ClearPoint Neuro, Inc.

2022-Q3 EPS reported -$0.50 revenue$12,017,000

Record revenue $4.6M (+30% YoY); biologics/drug delivery $2.1M (+39%).
Functional neurosurgery revenue $2.2M (+17%); capital equipment $0.4M (+78%).
Gross margin 68% vs 74% due to inventory reserves and overhead.
R&D spend $2.6M (+130%) driven by headcount and platform expansion.
Cash $57.7M; guidance: FY revenue $16-17.5M, case volume 900-1000.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.